RTP Mobile Logo
Year in Review: On Demand — Significance and Relevance of Recent Data Sets and Publications in the Management of Acute Leukemias
Released October 2018

Featuring key slides from the most important recent acute leukemia presentations and publications and a video interview with Dr Richard M Stone. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare professionals involved in the treatment of acute leukemias.

    The treatment of acute leukemias remains a challenge for many healthcare professionals and patients despite recent gains made in the management of this group of diseases. Determining which treatment approach is most appropriate requires careful consideration of patient-specific characteristics, physician expertise and available health-system resources. Published results from ongoing trials continually lead to the emergence of new therapeutic targets and regimens, thereby altering management algorithms. In order to offer optimal patient care, including the option of clinical trial participation, the practicing cancer clinician must be well informed of these advances.

    To bridge the gap between research and patient care, this video program features a one-on-one discussion with leading hematology-oncology investigator Dr Richard M Stone. By providing information on the latest clinical developments in the context of expert perspectives, this CME activity assists medical oncologists, hematologists, hematology-oncology fellows and other healthcare professionals with the formulation of evidence-based and current therapeutic strategies.


    • Evaluate the clinical relevance of recent pivotal research evidence specific to acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and acute promyelocytic leukemia (APL) as published in peer-reviewed journals and/or presented at major oncology conferences.
    • Review current data on recent treatment advances and updated practice standards, including FDA approvals, in acute leukemias, and integrate this information into current clinical care.
    • Identify the clinical and prognostic significance of specific cytogenetic and molecular abnormalities, and use this information to develop, adapt or refine current diagnostic testing algorithms for patients with AML.
    • Consider demographic and disease-related factors to guide the identification of patients with AML appropriate for treatment with induction therapy and/or stem cell transplantation.
    • Determine an evidence-based approach to the management of AML in elderly patients, considering the role of single-agent or combination therapy.
    • Assess available research evidence with existing and emerging FLT3-inhibiting agents, and use this information to guide clinical care and protocol opportunities for appropriate patients with AML.
    • Use the results of emerging clinical research in the optimization of treatment for young adult and adult patients with newly diagnosed and recurrent ALL.
    • Appraise existing efficacy and safety data from trials leading to the approval of chimeric antigen receptor (CAR) T-cell therapy in young adult patients with relapsed/refractory B-cell precursor ALL, and recall the scientific rationale supporting the ongoing investigation of novel applications of this treatment approach.
    • Understand the biological and clinical presentations associated with a diagnosis of APL, and develop an evidence-based approach to the management of low/intermediate- and high-risk disease in the up-front and relapsed settings.
    • Identify the mechanisms of action of and recall new data with promising investigational agents in acute forms of leukemia, and refer appropriate patients for participation in ongoing trials using these approaches.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    This CME activity consists of slide and video components.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY The following faculty (and his spouse/partner) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Richard M Stone, MD
    Director, Adult Leukemia Program
    Dana-Farber Cancer Institute
    Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Consulting Agreements: AbbVie Inc, Actinium Pharmaceuticals Inc, Agios Pharmaceuticals Inc, Amgen Inc, Argenx, Arog Pharmaceuticals Inc, Astellas Pharma Global Development Inc, Celator Pharmaceuticals Inc, Celgene Corporation, Fujifilm, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Juno Therapeutics, Karyopharm Therapeutics, Merck, Novartis, Orsenix, Otsuka America Pharmaceutical Inc, Pfizer Inc, Rafael Pharmaceuticals Inc, Roche Laboratories Inc, Seattle Genetics; Contracted Research: Novartis.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Astellas Pharma Global Development Inc, Celgene Corporation and Jazz Pharmaceuticals Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: October 2018
    Expiration date: October 2019

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):